Interviewing the Experts in Alzheimer Disease: A Continuation of Specialist Opinion and Data

Interviewing the Experts in Alzheimer Disease: A Continuation of Specialist Opinion and Data

Moderator
Susan Trieu, PharmD
Vice President, Trade Relations
SPARx
Southlake, Texas

Faculty Presenters

Gary Small, MD
Chair of Psychiatry
Hackensack University Medical Center

Physician in Chief for Behavioral Health
Hackensack Meridian Health
Hackensack, New Jersey

Winston Wong, PharmD
President
W-Squared Group
Longboat Key, Florida
 
Program Description
Before patients present with symptoms of Alzheimer disease (AD), neurons are affected due to inflammation and beta-amyloid plaques may accumulate. These plaques can often be observed with PET scans and allow for potential earlier diagnosis and therapeutic intervention. Beta-amyloid has been a focus of previous clinical trials, but research in tau antisense oligonucleotides and the protein ApoE4 in the setting of AD is expanding. Less than 5% of AD cases are considered to be the early-onset form, and early diagnosis may help improve patient quality of life and involvement in their care as well as decrease caregiver burden. To facilitate early identification of AD, managed care professionals and pharmacists must promote early identification of AD and include disease-modifying therapies into treatment protocols to preserve cognitive function in patients with AD. This interdisciplinary discussion will expand upon strategies presented at the AMCP 2020 Nexus conference that managed care professionals and pharmacists can use to collaborate to ensure guidelines for diagnosis and evaluation of AD and related dementias are incorporated into institutional management strategies.

Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: April 26, 2021
Expiration date: April 26, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Examine the clinical progression of Alzheimer disease (AD) and the value of biomarkers of disease in early diagnosis as they relate to treatment selection and patient management
• Analyze challenges in current treatment and management strategies in AD
• Classify clinical data for emerging disease-modifying therapies and their importance in early identification of disease
• Determine future managed care strategies that will allow for the uptake of future disease-modifying therapies in AD

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-161-H01-P. The activity is available for CE credit through April 26, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Gary Small, MD, has the following relevant financial relationships with commercial interests to disclose:

• Grant/Research Support: Handok, Theravalues
• Consultant: Acadia, Biogen
• Speakers Bureau: AARP, Acadia, Biogen, Allergan, Avanir, Genentech, Gerontological Society of America, Herbalife, Lundbeck, Novartis, Otsuka, Roche, RB Health
• Stock/Shareholder: Ceremark Pharma

Susan Trieu, PharmD, and Winston Wong, PharmD, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms